Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study

Byoung Chul Cho; Tommaso De Pas; Haralabos Kalofonos; Qun Wang; Rodryg Ramlau; Ying Cheng; Fabiana Vitiello; Tanel Laisaar; Eric Vallières; Bartosz Kubisa; Sergey Orlov; Keunchil Park; Channa Debruyne; Johan Vansteenkiste

doi:10.21873/anticanres.13255

Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study

Byoung Chul Cho, Tommaso De Pas, Haralabos Kalofonos, Qun Wang, Rodryg Ramlau, Ying Cheng, Fabiana Vitiello, Tanel Laisaar, Eric Vallières, Bartosz Kubisa, Sergey Orlov, Keunchil Park, Channa Debruyne, Johan Vansteenkiste

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Background/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.

Original language	English
Pages (from-to)	1403-1409
Number of pages	7
Journal	Anticancer research
Volume	39
Issue number	3
DOIs	https://doi.org/10.21873/anticanres.13255
Publication status	Published - 2019 Mar 1

Bibliographical note

Funding Information:
This work was supported by GlaxoSmithKline Biologicals SA that funded all costs associated to the study and the development and publishing of the present manuscript.

Publisher Copyright:
© 2019 International Institute of Anticancer Research. All Rights Reserved.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.13255

Cite this

@article{9800d30f417c4aa18d892644a4359912,

title = "Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study",

abstract = "Background/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.",

author = "Cho, {Byoung Chul} and {De Pas}, Tommaso and Haralabos Kalofonos and Qun Wang and Rodryg Ramlau and Ying Cheng and Fabiana Vitiello and Tanel Laisaar and Eric Valli{\`e}res and Bartosz Kubisa and Sergey Orlov and Keunchil Park and Channa Debruyne and Johan Vansteenkiste",

note = "Funding Information: This work was supported by GlaxoSmithKline Biologicals SA that funded all costs associated to the study and the development and publishing of the present manuscript. Publisher Copyright: {\textcopyright} 2019 International Institute of Anticancer Research. All Rights Reserved.",

year = "2019",

month = mar,

day = "1",

doi = "10.21873/anticanres.13255",

language = "English",

volume = "39",

pages = "1403--1409",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "3",

}

TY - JOUR

T1 - Prognostic factors in early-stage NSCLC

T2 - Analysis of the placebo group in the MAGRIT study

AU - Cho, Byoung Chul

AU - De Pas, Tommaso

AU - Kalofonos, Haralabos

AU - Wang, Qun

AU - Ramlau, Rodryg

AU - Cheng, Ying

AU - Vitiello, Fabiana

AU - Laisaar, Tanel

AU - Vallières, Eric

AU - Kubisa, Bartosz

AU - Orlov, Sergey

AU - Park, Keunchil

AU - Debruyne, Channa

AU - Vansteenkiste, Johan

N1 - Funding Information: This work was supported by GlaxoSmithKline Biologicals SA that funded all costs associated to the study and the development and publishing of the present manuscript. Publisher Copyright: © 2019 International Institute of Anticancer Research. All Rights Reserved.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.

AB - Background/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=85062644717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062644717&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13255

DO - 10.21873/anticanres.13255

M3 - Article

C2 - 30842175

AN - SCOPUS:85062644717

SN - 0250-7005

VL - 39

SP - 1403

EP - 1409

JO - Anticancer research

JF - Anticancer research

IS - 3

ER -

Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this